Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Coppo

Showing results (121-130 of 199) with videos related to

Pageof 20
Sort By:
British Journal of Haematology|September 4, 2024
Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpuraJulia Weisinger, Raïda Bouzid, Dana Ranta, et al.
The Lancet. Haematology|May 3, 2016
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathyEric Mariotte, Elie Azoulay, Lionel Galicier, et al.
Oncogene|June 25, 2003
Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cellsPaul Coppo, Isabelle Dusanter-Fourt, Gael Millot, et al.
Journal of Thrombosis and Haemostasis : JTH|November 7, 2019
Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES studyPaul Knoebl, Spero Cataland, Flora Peyvandi, et al.
Plos One|May 26, 2017
Predictive features of chronic kidney disease in atypical haemolytic uremic syndromeMatthieu Jamme, Quentin Raimbourg, Dominique Chauveau, et al.
Journal of Thrombosis and Haemostasis : JTH|September 11, 2020
ISTH guidelines for treatment of thrombotic thrombocytopenic purpuraX Long Zheng, Sara K Vesely, Spero R Cataland, et al.
Journal of Thrombosis and Haemostasis : JTH|September 11, 2020
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpuraX Long Zheng, Sara K Vesely, Spero R Cataland, et al.
Clinical Hematology International|January 7, 2025
Incidence and impact of other malignancies after immunochemotherapy by fludarabine, cyclophosphamide, and rituximab as frontline treatment for chronic lymphocytic leukemia: A single-center retrospective studyNicolas Stocker, Tamim Alsuliman, Elise Corre, et al.
Haematologica|December 8, 2018
Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patientsAn-Sofie Schelpe, Elien Roose, Bérangère S Joly, et al.
Journal of Thrombosis and Haemostasis : JTH|September 11, 2020
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpuraX Long Zheng, Sara K Vesely, Spero R Cataland, et al.
Pageof 20

Showing results (121-130 of 199) with videos related to

Sort By:
Pageof 20
British Journal of Haematology|September 4, 2024
Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpuraJulia Weisinger, Raïda Bouzid, Dana Ranta, et al.
The Lancet. Haematology|May 3, 2016
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathyEric Mariotte, Elie Azoulay, Lionel Galicier, et al.
Oncogene|June 25, 2003
Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cellsPaul Coppo, Isabelle Dusanter-Fourt, Gael Millot, et al.
Journal of Thrombosis and Haemostasis : JTH|November 7, 2019
Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES studyPaul Knoebl, Spero Cataland, Flora Peyvandi, et al.
Plos One|May 26, 2017
Predictive features of chronic kidney disease in atypical haemolytic uremic syndromeMatthieu Jamme, Quentin Raimbourg, Dominique Chauveau, et al.
Journal of Thrombosis and Haemostasis : JTH|September 11, 2020
ISTH guidelines for treatment of thrombotic thrombocytopenic purpuraX Long Zheng, Sara K Vesely, Spero R Cataland, et al.
Journal of Thrombosis and Haemostasis : JTH|September 11, 2020
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpuraX Long Zheng, Sara K Vesely, Spero R Cataland, et al.
Clinical Hematology International|January 7, 2025
Incidence and impact of other malignancies after immunochemotherapy by fludarabine, cyclophosphamide, and rituximab as frontline treatment for chronic lymphocytic leukemia: A single-center retrospective studyNicolas Stocker, Tamim Alsuliman, Elise Corre, et al.
Haematologica|December 8, 2018
Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patientsAn-Sofie Schelpe, Elien Roose, Bérangère S Joly, et al.
Journal of Thrombosis and Haemostasis : JTH|September 11, 2020
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpuraX Long Zheng, Sara K Vesely, Spero R Cataland, et al.
Pageof 20